Epidemiology
Reporting Obligations
Carbapenemase-producing Enterobacteriaceae (CPE) Infection is designated as a disease of public health significance and is reportable under the Ontario Health Protection and Promotion Act. Report suspect and confirmed cases within one business day to the local Health Unit.
Aetiologic Agent
Carbapenemase-producing Enterobacteriaceae (CPE) refers to
Gram-negative bacteria belonging to the Enterobactericeae family harbouring
carbapenemase-encoding genes. Carbapenemases are beta-lactamases with
ability to hydrolyze penicillins, cephalosporins, and carbapenems,
rendering these antibiotics ineffective. As a result, there are limited
antibiotic treatment options for patients with infection due to CPE and
mortality is substantially increased.
The carbapenemases that are most common in Ontario currently include;
New-Delhi Metallobetalactamase (NDM), Klebsiella pneumoniae (KPC),
oxacillinase (OXA-48) and Verona integron-encoded metallo-betalactamases
(VIM).
Clinical Presentation
Patients with CPE colonization are asymptomatic and can only be identified
by active screening; however, colonizing CPE can cause infections if they
gain access to sterile body sites (e.g., lungs, bladder, bloodstream).
CPE are capable of causing difficult-to-treat infections in any part of the
body, including pneumonia, bloodstream infections, intra-abdominal
infections, urinary tract infections, and central venous catheter
infections. Mortality in patients with CPE bacteremia may be up to 50%.
Modes of Transmission
Transmission of CPE occurs via direct or indirect contact.
CPE are isolated predominantly from patients with exposures in health care
facilities and can spread from person to person on the hands of healthcare
workers or via shared medical equipment, particularly when hand hygiene is
missed or equipment is not properly cleaned and disinfected. Transmission
has also been associated with contaminated sink drains and outbreaks have
occurred where CPE was transmitted between patients undergoing
duodenoscopy, even when it appears that the duodenoscope was appropriately
reprocessed between patients.
The incubation period for exposure-to-illness onset is undefined.
Individuals colonized with CPE may remain asymptomatic if they are in good
health and undergo required medical procedures but can still act as a
reservoir for transmission to others.
Factors that impair the function of the immune system (e.g. hematologic
malignancy), and interventions which permit colonizing bacteria to invade
(e.g. indwelling devices) increase the probability of infection with CPE.
Period of Communicability
The period of communicability of CPE persists as long as the organism is
present in the gastrointestinal tract of the patient. Several studies have
evaluated duration of colonization of patient populations in different
countries with varying results. Patients can be intermittently positive on
repeat screening and may be colonized for months to years.
Risk Factors/Susceptibility
The primary risk factor for acquiring CPE is exposure to patients in health
care facilities with prevalent CPE. Patients who have received health care
outside of the country or who are known contacts of CPE should be screened.
People coming from the Indian subcontinent with or without exposure to
health care, are also at risk.
Diagnosis & Laboratory Testing
CPE are identified by any Ontario microbiology laboratory. A case of CPE is
any patient with a positive isolate of CPE, regardless of the presence of
signs and symptoms of clinical findings.
See Labstract.
Treatment & Case Management
Because CPE are resistant to all penicillins, cephalosporins, and
carbapenems, treatment of infections is difficult and involves the use of
antibiotics with poor adverse event profiles and/or reduced efficacy (e.g.,
colistin, tigecycline). The isolation of CPE should be considered to be a
critical laboratory result.
For case management recommendations, refer to the Provincial Infectious
Diseases Advisory Committee, Annex A document “Screening, Testing and
Surveillance for Antibiotic-Resistant Organisms (AROs)”. Current expert
recommendations are that patients remain on contact precautions for the
duration of hospitalization. Pay particular attention to sink cleaning and
disinfection.
Patient Information
Additional Resources
Public Health Ontario. Annex A: Screening, Testing and Surveillance for
Antibiotic-Resistant Organisms (AROs) In All Health Care Settings,
February 2013.
Centers for Disease Control and Prevention. “Facility Guidance for
Control of Carbapenem-resistant Enterobacteriaceae (CRE)”, 2015.
Public Health Ontario. “Carbapenemase-Producing Enterobacteriaceae (CPE)”, includes CPE Frequently Asked Questions and other resources.
References
Ministry of Health, Infectious Diseases Protocol - Ontario Public Health Standards, 2022.